Brickell Biotech announces the sale of sofpironium bromide to Botanix Pharmaceuticals

Brickell Biotech announces the update of the annual shareholders’ meeting

Brickell Biotech

Meeting updated on May 17, 2022 at 10 MT

Brickell encourages all shareholders registered on March 7, 2022 who have not yet voted to do so by 11:59 pm Eastern time May 16, 2022

BOULDER, Colo., May 3, 2022 (GLOBE NEWSWIRE) – Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”) announced today that its 2022 Annual Shareholders’ Meeting (the “Annual Meeting”) is was updated as of Tuesday, May 17, 2022 at 10:00 Mountain Time with respect to all proposals described in Brickell’s final proxy statement filed with the US Securities and Exchange Commission (the “SEC”) on March 22, 2022 (the “Statement of Delegation “).

The Annual Meeting will continue to be held at the offices of Brickell Biotech, Inc., 5777 Central Avenue, Suite 102, Boulder, Colorado 80301. Additionally, the record date for determining eligible shareholders at the Annual Meeting will be closed for activity on 7 March 2022.

During the current update, Brickell continues to solicit votes from its shareholders with respect to all proposals contained in the proxy statement. At the time of the update of the Annual Meeting, the proxies had been presented by shareholders representing approximately 51% of the Brickell ordinary shares in circulation and with voting rights, which constituted the quorum, but was not sufficient to approve Proposal 3 , Approval of an amendment to Brickell’s reformulated deed of incorporation to increase the number of authorized common shares, or Proposal 5, Approval of the reverse stock split and Proposal to reduce the authorized shares, each requiring approval by the holders of the majority of the outstanding common stock of Brickell stock. Proxies previously presented in relation to the Annual Shareholders ‘Meeting will be voted on all proposals in the updated Annual Shareholders’ Meeting unless they are appropriately revoked and shareholders who have previously presented a proxy or otherwise voted do not have to take any action.

Brickell encourages all shareholders registered on March 7, 2022 who have not yet voted to do so by 11:59 pm Eastern time on May 16, 2022.

Important information

This material may be considered solicitation material in connection with the Annual Assembly which will be reconvened on May 17, 2022. In connection with the Annual Assembly, Brickell filed the proxy statement. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS ARE INVITED TO READ THE STATEMENT OF DELEGATION AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. No changes were made to the proposals to be submitted to the vote of the shareholders at the Annual Meeting. Brickell’s proxy statement and any other materials Brickell filed with the SEC can be obtained free of charge on the SEC’s website at https://www.sec.gov or on the Brickell’s website at https: // www.brickellbio.com.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company that strives to transform patients’ lives by developing innovative and differentiated prescribed therapies for the treatment of autoimmune, inflammatory and other debilitating diseases. Brickell’s pipeline includes several candidates in development and a state-of-the-art platform with broad potential in autoimmune and inflammatory disorders. This includes BBI-02, a potential first-in-class, phase 1-ready oral DYRK1A inhibitor with strong preclinical validation for the treatment of autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis and type 1 diabetes, BBI- 10, a novel preclinical oral STING inhibitor that demonstrated dose-dependent reduction of cytokines in non-clinical studies providing evidence of the mechanism for the treatment of autoinflammatory and rare genetic conditions and a platform of kinase inhibitors DYRK, CLK, LRRK2 and next-generation TTK with the potential to produce treatments for autoimmune, inflammatory and other debilitating conditions. Brickell’s executive management team and board of directors have extensive experience in product development and global marketing, having held leadership roles in large global pharmaceutical and biotech companies that have developed and / or launched successful products, including many first class and / or achieved iconic status, such as Cialis®Valtz®Gemzar®Prozac®Cymbalta®and Juvederm®. Brickell’s strategy is to leverage this experience to license, acquire, develop and commercialize innovative pharmaceutical products that Brickell believes can significantly benefit patients suffering from chronic and debilitating diseases who are underserved by available therapies. For more information, visit https://www.brickellbio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements made in this press release relating to future financial, commercial and / or research and clinical performance, conditions, plans, prospects, trends or strategies and other similar matters, including without limitation Brickell’s strategy; future operations; future financial position; future liquidity; future income; territorial focus; expected expenses; results of operations; the anticipated timing, scope, design, progress, results and / or data disclosure of ongoing and future clinical and non-clinical studies; intellectual property rights, including their acquisition, validity, duration and enforceability; the expected timing and / or results of regulatory submissions and approvals; and the prospects for commercialization of any candidate product of Brickell or any third party, or the research and / or licensing of partnerships or actions of its partners, including the United States, Japan, South Korea or any other country are statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Also, when or if used in this press release, the words “may”, “may”, “should”, “may”, “anticipate” , “believe,” “estimate”, “expect”, “mean”, “plan”, “foresee”, “potential”, “will”, evaluate “,” advance “,” excited “,” aim “,” strive “,” help “,” progress “,” select “,” start “,” look ahead “,” promise “and similar expressions and their variants, as they refer to Brickell or any of Brickell’s partners, or to third parties parties, may identify statements Brickell cautions that these forward-looking statements are subject to you to numerous assumptions, risks and uncertainties, which change over time, often rapidly and in unexpected ways. Important factors that could cause actual results to differ materially from the results discussed in forward-looking statements or historical experience include risks and uncertainties, including but not limited to research results and data that do not meet objectives, expectations or regulatory approval requirements. ; ability to obtain adequate funding for product development, regulatory submissions and any commercialization; ability to acquire, maintain and enforce intellectual property rights; potential delays or alterations in product development, testing of any kind and regulatory submissions and reviews; changes in law or policy; litigation; feedback or requests from the regulatory agency; supply chain disruptions; unexpected requests for cash resources; disruptions and negative effects related to the COVID-19 pandemic and / or the conflict in Ukraine; interruptions, interruptions or inability by Brickell, its partners or third parties to obtain or supply research material, raw materials and / or products anywhere, or to guarantee essential services, in the world; efforts to obtain and maintain adequate prices and adequate reimbursements and other insurance coverage for our products; the result of Brickell’s current and planned preclinical and clinical studies in our portfolio; and other risks associated with developing and obtaining regulatory approval for and marketing candidate products.

Further information on the factors and risks that could cause actual results to differ from any forward-looking statements is contained in Brickell’s SEC filings, available at https://www.sec.gov (or https: // www .sec.gov .brickellbio.com). Forward-looking statements represent only Brickell’s estimates as of the date of this document. Brickell expressly disclaims any obligation or obligation to update any forward-looking statements.

Brickell Investor Contact:
Dan Ferry
LifeSci Consultants
(617) 430-7576
daniel@lifesciadvisors.com

Leave a Comment

Your email address will not be published.